We previously reported the Bcl-2/Bcl-xL-bispecific activity of the 2Ј-O-(2-methoxy)ethyl (2Ј-MOE)-modified gapmer antisense oligonucleotide 4625. This oligonucleotide has 100% complementarity to Bcl-2 and three mismatches to Bcl-xL. In the present study, the isosequential locked nucleic acid (LNA)-modified oligonucleotide 5005 was generated, and its ability to further improve the downregulation of the two antiapoptotic targets in tumor cells was examined. We demonstrate that compared with 4625, 5005 more effectively decreased the expression of the mismatching Bcl-xL target gene in MDA-MB-231 breast and H125 lung cancer cells. In both cell lines, antisense activity caused decreased cell viability by induction of apoptosis. Moreover, in combination with various anticancer agents, 5005 reduced tumor cell viability more effectively than 4625. We describe for the first time the functional comparison of isosequential Bcl-2/Bcl-xL-bispecific 2Ј-MOE and LNA-modified antisense oligonucleotides and report that the LNA analog more effectively downregulated the two apoptosis inhibitors overexpressed in human tumors. Our data underscore the ability of LNA modifications to enhance the efficacy and favorably modulate the target specificity of antisense oligonucleotides.
INTRODUCTION O
VEREXPRESSION OF Bcl-2 AND Bcl-xL PROVIDES cancer cells with a survival advantage and inherent resistance to apoptosis. Both proteins control a common apoptosis signaling pathway that involves the mitochondria and causes the activation of effector caspases (Cory and Adams, 2002) . This pathway is commonly activated by various stress stimuli, such as DNA damage or oncogene activation, and also plays a role in amplification of the death receptor pathway (Johnstone et al., 2002) . Anticancer agents kill target cells mainly by induction of mitochondrial apoptosis, which explains why increased expression of the antiapoptotic Bcl-2 family members Bcl-2 and Bcl-xL confers resistance to a broad range of anticancer agents (Gazitt et al., 1998; Heere-Ress et al., 2002; Kojima et al., 1998; NicAmhlaoibh et al., 1999; Sartorius and Krammer, 2002) . Their downregulation using antisense technology has potential to facilitate tumor cell apoptosis and overcome the resistance phenotype (Heere-Ress et al., 2002; Miyake et al., 2000; Zangemeister-Wittke et al., 1998) . Bcl-2 and Bcl-xL are differentially expressed in heterogeneous tumor cell populations, have similar modes of action, and may inhibit apoptosis in a cooperative manner (Kojima et al., 1998; NicAmhlaoibh et al., 1999; Sartorius and Krammer, 2002) . As all known human tumors express either Bcl-2 or Bcl-xL or both proMolecular Oncology Laboratory, Department of Oncology, University Hospital Zurich, Zurich, Switzerland. Page numbers are temporary.
teins together, an antisense strategy targeting Bcl-2 and Bcl-xL simultaneously has broad clinical applicability and is likely to show increased efficacy over one directed against a single target only.
The 2Ј-O-(2 methoxy)ethyl (2Ј-MOE)-modified gapmer oligonucleotide 4625 is 100% complementary to Bcl-2 mRNA and has three mismatches to Bcl-xL (Zangemeister-Wittke et al., 2000) . At concentrations above 200 nM, it effectively downregulates Bcl-2 and Bcl-xL in tumor cells (Gautschi et al., 2001 ), whereas at lower concentrations, the effect on Bcl-2 prevails. The bispecific activity of 4625 facilitates apoptosis in various tumor cell types, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), melanoma, breast, colon, and prostate cancer (Gautschi et al., 2001; Olie et al., 2002a) . It is conceivable, however, that in a significant number of tumors in which Bcl-xL alone is sufficient to protect from apoptosis (Grad et al., 2000) , the proapoptotic effect of 4625 may be attenuated by its lower affinity for the mismatching target mRNA.
In the present study, an isosequential analog of 4625, oligonucleotide 5005, was developed that employs the locked nucleic acid (LNA) chemistry (Petersen and Wengel, 2003) to further increase its antisense activity and, particularly, to overcome the destabilizing effect of the mismatches on Bcl-xL mRNA hybridization. The ability of 5005 to simultaneously downregulate Bcl-2 and BclxL expression at the mRNA and protein levels in order to facilitate apoptosis and sensitize tumor cells to clinically relevant anticancer agents is demonstrated.
MATERIALS AND METHODS

Tumor cell lines
The breast cancer cell line MDA-MB-231 was cultured in Dulbecco's modified Eagle's medium (DMEM) containing 4.5 g/L glucose and pyridoxine HCl, supplemented with 10% fetal bovine serum (FBS) (Hyclone Europe, Ltd., Cramlington, UK), 2 mM L-glutamine, 50 IU/ml penicillin, and 50 g/ml streptomycin. The NSCLC cell line NCI-H125 (H125) was cultured in RPMI 1640 (Hyclone), supplemented with 10% FBS, 50 IU/ml penicillin, and 50 g/ml streptomycin. Cells were cultured at 37°C in a humidified atmosphere containing 5% CO 2 . Both cell lines were obtained from American Type Culture Collection (ATCC, Rockville, MD).
Treatment of cells with oligonucleotides
Oligonucleotides were delivered into cells in the form of complexes with Lipofectin (Life Technologies, Glasgow, U.K.) as described by Ziegler et al. (2000) . Antisense oligonucleotides 4625 and 5005 are isosequential 20-mer gapmer oligonucleotides with a full phosphorothioate backbone and the sequence 5Ј-AsAsGsGsCsAsTsCsCsCsAsGsCsCsTsCsCsGsTsT-3Ј. Ribose modifications, which are 2Ј-MOE in 4625 and LNA in 5005, are indicated by underlined letters. Oligonucleotides 5007, 5008, and 5009 are mismatch controls to 5005 with the sequences 5Ј-AsAsAsGsCsAsTsCsCsCsAsGsCsCsTsCsCsGsTsT-3Ј, 5Ј-AsAsGsGsCsAsTsCsCsCsAsGsCsCsGsCsCsGsTsT-3Ј, and 5Ј-AsAsGsGsTsAsTsCsCsCsAsGsCsCsTsCsCsGsTsT-3Ј, respectively. Oligonucleotides 4626 and 5006 with the sequence 5Ј-CsAsCsGsTsCsAsCsGsCsGsCsGsCsAsCsTsAsTsT-3Ј are scrambled controls to 4625 and 5005, respectively. The 2Ј-MOE-modified oligonucleotides were synthesized using an Applied Biosystems 394 automated DNA synthesizer (Foster City, CA) as described by Simões-Wüst et al. (2002) . LNA oligonucleotides were purchased from Proligo France SAS (Paris, France). A BLAST search of the NCBI database revealed no homology of these sequences to other known human genes.
Anticancer agents
Doxorubicin and paclitaxel were obtained from Sigma Chemical (St. Louis, MO), cisplatin (Platinol) from Bristol-Myers Squibb (New York, NY), and gemcitabine (Gemzar) from Eli Lilly (Vienna, Austria).
Real-time polymerase chain reaction (PCR)
Total RNA was isolated from cells using the RNeasy Mini kit (Qiagen, Inc., Santa Clarita, CA), and cDNA synthesis was performed using Taqman Reverse Transcription reagents (Perkin-Elmer Applied Biosystems, Foster City, CA). All sequences were amplified with an ABI Prism 7700 Sequence Detection System following the corresponding user manual instructions. Bcl-2, BclxL, and survivin were amplified using previously described primers and Taqman probes, and their amounts were quantified relative to rRNA using the comparative CT method Zangemeister-Wittke et al., 2000) . To amplify other sequences, Assays-on-Demand (Applied Biosystems) were used, and the data were quantified using calibration curves. For each amplified sequence within each cell line, the amount present in untreated cells kept under identical conditions was taken as 100%. IC 50 (concentration at which the effect is inhibited by 50%) values were determined in three independent experiments performed in quadruplicate. 
Detection of
by Western blotting
Cell lysates were subjected to Western blot analysis as described by Zangemeister-Wittke et al. (2000) . Briefly, 30-100 g soluble protein per sample was separated on 12% polyacrylamide SDS gels, and transfer to polyvinylidene fluoride membranes was performed in semidry blotting chambers for 90 minutes. The blots were blocked in Tris-buffered saline containing 5% bovine serum and 5% nonfat milk and then incubated for 2 hours at ambient temperature (or overnight at 4°C) with either mouse antihuman Bcl-2 monoclonal antibody (mAb) (Dako Diagnostics AG, Glostrup, Denmark), rabbit antihuman Bcl-xL polyclonal antibody (Transduction Laboratories, Lexington, KY), or goat antihuman ICAD polyclonal antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA). ␤-Actin detected with a mouse antiactin mAb (ICN Biomedicals Inc., Aurora, OH) was used to control for equal protein loading. Blots were incubated with either rabbit antimouse or goat antirabbit immunoglobulin peroxidase conjugates (Sigma) for 1.5 hours at ambient temperature, and immunocomplexes were visualized by enhanced chemiluminescence (ECL) using the ECL TM kit (Amersham Pharmacia, Biotech, Dübendorf, Switzerland), followed by exposure to x-ray films.
Measurement of cell viability
Cell viability was determined by use of a colorimetric assay as described by Leech et al. (2000) . Cells were plated in 96-well plates at 7500 (MDA-MB-231 cell line) or 5000 (H125) cells/well and treated in the absence or presence of oligonucleotides for 6 hours. The culture medium was renewed, and cells were further incubated in some experiments in the presence of anticancer agents up to 72 hours after the addition of oligonucleotides. The MTT reagent was added (10 l/well of a 10 mg/ml solution in phosphate-buffered saline [PBS] ) and allowed to react for 90 minutes at 37°C before the reaction was stopped by the addition of 100 l/well 20% SDS in a 1:1 solution of dimethylformamide/water (pH 4.7, adjusted with acetate/1 M HCl, 4:1). After overnight solubilization, MTT cleavage was monitored at 570 nm by use of a SPECTRAmax 340 microplate reader (Molecular Devices, Sunnyvale, CA). The absorbance value obtained with untreated cells kept under identical conditions was taken as 100%.
Caspase-3-like protease activity assay
Caspase-3-like protease activity in cell lysates was analyzed using the Caspase-3 Colorimetric Assay Kit (Alexis Corporation, Lausen, Switzerland) following the manufacturer's instructions. Cleavage of the labeled substrate DEVD-pNA was monitored at 405 nm using a SPECTRAmax 340 microplate reader. Caspase-3-like protease activity in apoptotic cells was calculated as fold increase of the absorbance signal obtained with lysates of untreated (viable) cells kept under identical conditions.
RESULTS
Oligonucleotide 5005 downregulates Bcl-xL more effectively than 4625
To enhance the effect of the 2Ј-MOE oligonucleotide 4625 on the mismatching Bcl-xL mRNA, the isosequential oligonucleotide 5005 was designed, in which the 2Ј-MOE nucleosides were replaced by LNA nucleosides. The effects of 5005 and 4625 on the Bcl-2 (Fig. 1A) and the Bcl-xL (Fig. 1B) mRNA were compared in MDA-MB-231 breast cancer cells, which express relatively high amounts of both transcripts . Oligonucleotide 5005 decreased Bcl-xL expression more effectively than 4625 at all concentrations tested (Fig. 1B) , whereas the difference on the Bcl-2 target was less pronounced and most apparent at lower concentrations (Fig. 1A) . The IC 50 values on the Bcl-xL mRNA were 97 Ϯ 18 nM for 5005 and 253 Ϯ 22 nM for 4625 (p Ͻ 0.01, paired Student's t-test). On the Bcl-2 mRNA, IC 50 values of 65 Ϯ 12 nM and 109 Ϯ 20 nM were obtained for oligonucleotides 5005 and 4625, respectively. The scrambled control oligonucleotides 4626 and 5006 had no effect on Bcl-2 and Bcl-xL expression. Compared with oligonucleotide 5005, which has three mismatches to Bcl-xL and none to Bcl-2, each of the LNA control oligonucleotides 5007, 5008, and 5009 has two mismatches to Bcl-xL and one to Bcl-2. The Bcl-2 mismatch slightly decreased the antisense effect on this target (Fig. 1A) , indicating a true antisense mechanism of action. On the other hand, reducing the three Bcl-xL mismatches in 5005 to two mismatches in the controls did not further increase Bcl-xL antisense activity (Fig. 1B) . Therefore, only oligonucleotide 5005 was used in subsequent experiments. Figure 1C depicts the time dependency of Bcl-xL mRNA downregulation mediated by oligonucleotides 5005 and 4625. The difference in BclxL downregulation caused by the two oligonucleotides was already obvious after 2 hours of treatment and gradually increased with time. An effective downregulation of Bcl-xL by oligonucleotide 5005 was also observed in the H125 NSCLC cell line, in which IC 50 values on the Bcl-xL mRNA of 80 Ϯ 27 nM for 5005 and Ͼ300 nM for 4625 were obtained (data not shown). Similar to MDA-MB-231 cells, there was no difference in Bcl-2 antisense activity, with IC 50 values of 71 Ϯ 10 nM and 72 Ϯ 2 nM for oligonucleotide 5005 and 4625, respectively (data not shown).
Enhancing the mRNA binding affinity of antisense oligonucleotides to overcome the destabilizing effect of base mismatches may result in unwanted antisense activity against off-target genes. To exclude this possibility, we analyzed the effects of 5005 and 4625 on the expression of the related antiapoptotic Bcl-2 family member Bcl-W (Cory and Adams, 2002) in MDA-MB-231 cells.
In addition, the effects of the oligonucleotides on the mRNAs of survivin, an inhibitor of apoptosis proteins that might be downregulated during cell cycle arrest, of the survival and stress kinase Akt, and of p53 were investigated. As shown in Figure 1D , antisense treatment did not significantly modulate the expression of these irrelevant mRNAs.
Downregulation of Bcl-2 and Bcl-xL mRNA causes decreased protein levels
MDA-MB-231 cells coexpress relatively high levels of Bcl-2 and Bcl-xL proteins, which are readily detectable by Western blot analysis ( Fig. 2A , untreated lane, and Fig. 2C) . Treatment of cells with 5005 or 4625 caused a visible downregulation of both proteins. At the lowest concentration tested (150 nM), the antisense effect of 4625 on Bcl-xL was suboptimal, whereas 5005 effectively inhibited Bcl-xL expression. The pattern of protein downregulation confirmed the data obtained on the mRNA level. Similar to MDA-MB-231 cells, treatment of H125 cells with 5005 or 4625 also resulted in downregulation of both targets on the mRNA and protein levels (Fig. 2B) , with a superior effect of 5005 on Bcl-xL. The basal levels of Bcl-2 and Bcl-xL in H125 and MDA-MB-231 cells were found to be similar (Fig. 2C) .
Increased antisense activity of 5005 causes decreased cell viability
It is conceivable that the observed functional superiority of 5005, which downregulated Bcl-xL more effectively than did 4625, may result in stronger proapoptotic activity. To investigate this, the effects of the two anti- 
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sense oligonucleotides on cell viability were measured. Both 5005 and 4625 decreased MDA-MB-231 (Fig. 3A) and H125 (Fig. 3B ) cell viability. In both cell lines, the effect of 5005 was more pronounced than that of the 2Ј-MOE counterpart. Microscopic examination revealed that antisense-treated cells showed morphologic hallmarks of apoptosis, such as detachment from culture plate, rounding up, and decrease in size (data not shown). The scrambled control oligonucleotides had no effect on MDA-MB-231 cell viability and showed signs of cytotoxicity only in H125 cells when used at concentrations Ͼ200 nM. In both cell lines, death was associated with activation of a cascade of proapoptotic events culminating in caspase-3 activation and cleavage of its substrate ICAD (Figs. 4 and 6 ).
Increased antisense activity of 5005 causes increased chemosensitization
Having demonstrated that the effective downregulation of Bcl-2 and Bcl-xL using higher concentrations of 4625 and 5005 sufficed to reduce tumor cell viability, we investigated whether the antisense oligonucleotides at low concentrations were still capable of facilitating apoptosis induced by chemotherapy. Tumor cells were pretreated with 50-100 nM oligonucleotide 5005 or 4625, followed by the addition of various anticancer agents at doses below their IC 50 values. These were calculated as 200 nM for doxorubicin and 170 nM for paclitaxel in MDA-MB-231 cells and 4 M for cisplatin, 75 nM for paclitaxel, and 34 nM for gemcitabine in H125 cells. In Figure 5 , the effects of the various combinations on cell viability are depicted. Under the chosen conditions, 5005, but not 4625, was able to reduce cell viability to Ͻ50% when used as a single agent. In addition, the effects of 4625 or 5005 in combination with the various anticancer agents were stronger than those of the single agents alone in both MDA-MB-231 (Fig. 5A) and H125 (Fig. 5B) 
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and 5006 on cell viability were marginal, both in the absence and in the presence of the anticancer agents.
As shown in Figure 6 , the reduction in cell viability depicted in Figure 5 correlated with the induction of caspase-3 activity in lysates prepared from the treated cells. Note that, similar to the cell viability data, at these suboptimal oligonucleotide concentrations, there was a clear difference in the abilities of 5005 and 4625 to activate caspase-3 when used as single agents. In H125 cells, the concentrations of anticancer agents used in combination treatment viability assays led to high caspase-3-like activity (data not shown), which hindered the comparison of the cell's response to the various treatments. Therefore, in these experiments, lower concentrations of cytotoxic anticancer agents were chosen (Fig. 6B) .
DISCUSSION
The antiapoptotic proteins Bcl-2 and Bcl-xL are expressed in all known human tumors, either alone or together, and even within a single tumor cell population, their levels may vary. The therapeutic value of an antisense approach targeting Bcl-2 and Bcl-xL increases with its ability to simultaneously downregulate both proteins together and, hence, to facilitate apoptosis in a large fraction of tumor cells and in a broad range of different tumor types. In a previous study, we compared isosequential antisense oligonucleotides targeting a high homology region between Bcl-2 and Bcl-xL, including a full-phosphorothioate backbone without 2Ј-ribose modifications, a mixed phosphorothioate and phosphodiester 
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backbone with 2Ј-MOE modifications, a full-phosphorothioate backbone with 2Ј-O-methyl modifications, and a mixed phosphorothioate and phosphodiester backbone with 2Ј-O-methyl modifications. The data unveiled the oligonucleotide in the full-phosphorothioated 2Ј-MOEmodified gapmer format (4625) as the most potent antisense compound (Olie et al., 2002b) . Nevertheless, the IC 50 value for downregulating the expression of Bcl-xL was higher than that for Bcl-2 (Gautschi et al., 2001) , probably due to the three base mismatches and the resulting lower hybridization affinity to the Bcl-xL mRNA. In the present study, we investigated whether replacing the 2Ј-MOE residues with higher affinity LNA nucleosides further increases the activity of 4625, and particularly its effect on Bcl-xL.
LNA bases are ribonucleotide analogs containing a methylene linkage between the 2Ј-oxygen and three 4'-carbon of the ribose ring. The constraint on the sugar moiety results in a locked 3Ј-endo conformation that preorganizes the base for hybridization and increases the melting temperature by up to 10°C per base (Petersen and Wengel, 2003) . The favorable biophysical properties of LNA oligonucleotides make improvements in a wide range of applications possible. These include the induction of single nucleotide exchange reactions in vivo (Parekh-Olmedo et al., 2002) , genotyping of single nucleotide polymorphisms (SNPs) (Jacobsen et al., 2002; Simeonov and Nikiforov, 2002; Ugozzoli et al., 2004) , induction of RNA misfolding (Childs et al., 2002) , improvement of DNAzymes (Vester et al., 2004) , support 
of complicated PCR techniques (Latorra et al., 2003) , and addition of functionality to plasmid DNA (Hertoghs et al., 2003) . Several LNA oligonucleotides have been reported for conventional antisense approaches; examples include those targeting a G-protein-coupled receptor (Wahlestedt et al., 2000) , HIV-1 TAR (Arzumanov et al., 2001) , RNA polymerase II (Fluiter et al., 2003) , telomerase (Elayadi et al., 2002) , the vanilloid receptor (Grunweller et al., 2003; Kurreck et al., 2002) , and the lipocalin-type prostaglandin D synthase (Mong et al., 2003) . Candidate targets that are implicated in the negative regulation of apoptosis and thus involved in malignant transformation and tumor progression have not yet been investigated. Treatment of tumor cells with the LNA-modified 5-10-5 gapmer 5005 reduced the amount of target RNAs, indicating its ability to mobilize RNase H as a major antisense mechanism. This possibility is supported by a recent study showing that a gap of 10 bases in a LNA-modified oligonucleotide supports activation of this endonuclease in a sequence-independent manner (Frieden et al., 2003) . As expected from the improved RNA hybridization affinity provided by the LNA building blocks, oligonucleotide 5005 downregulated Bcl-2 and particularly Bcl-xL expression more effectively than its isosequential 2Ј-MOE counterpart 4625.
Other studies demonstrated that the activity of LNA oligonucleotides against the vanilloid receptor also compared favorably with that of 2Ј-O-methyl oligonucleotides (Grunweller et al., 2003) . The increase in BclxL downregulation achieved with the LNA modification shows that gain in hybridization affinity not only translates into increased antisense activity against a fully matching target but also helps to overcome the destabilizing effect of base mismatches in an antisense oligonucleotide sequence. This functional property may assist in designing antisense activity against more than one target in a controlled manner. Another recent technology that deserves attention for use in targeted gene silencing takes advantage of the process of RNA interference (RNAi) by use of short doublestranded RNA (small interfering RNA [siRNA]) (McManus and Sharp, 2002) . Although siRNAs and conventional RNase H-dependent antisense oligonucleotides recruit and activate different enzymatic processes, the activity and tolerance for mismatching bases of siRNAs and second-generation 2Ј-MOE-modified oligonucleotides seem to be very similar (Vickers et al., 2003) . siRNA targeting the site of 5005 and 4625 hybridization in the Bcl-2 and Bcl-xL mRNA revealed a slightly lower degree of bispecific antisense activity compared with the 2Ј-MOE oligonucleotide 4625 (A.P. Simões-Wüst, unpublished observations).
The LNA analog 5005 decreased the viability of MDA-MB-231 breast cancer and H125 NSCLC cells more effectively than did 4625. We believe that this was due to the improved antisense effect on Bcl-xL, which acts as a potent apoptosis inhibitor in both cell types. To what extent increased bispecific antisense activity and proapoptotic effect translate into increased therapeutic efficacy in vivo remains to be investigated. In addition, the in vivo toxicity profile of LNA oligonucleotides is a significant subject of ongoing investigations. Several studies have shown that the nonantisense-related cytotoxicity of LNA oligonucleotides is favorably low (Fluiter et al., 2003; Wahlestedt et al., 2000) , and LNA modifications seem to reduce the immunostimulatory effect of CpG-containing oligonucleotides (Vollmer et al., 2004) . There is increasing evidence pointing to a major role of Bcl-2 and Bcl-xL in broad-spectrum drug resistance. Almost all anticancer agents induce apoptosis via activation of the intrinsic mitochondrial pathway, which is negatively regulated by these two antiapoptotic proteins (Kaufmann and Vaux, 2003) . To investigate the ability of oligonucleotide 5005 to sensitize tumor cells to chemotherapy in a clinically relevant setting, we focused on anticancer agents with different modes of action that are routinely used for the treatment of breast or lung cancer (Fornier et al., 1999) . The experimental conditions were chosen to reduce the cytotoxic effect when the anticancer agents were used alone. In all cases, pretreatment with oligonucleotide 4625 and more profoundly with 5005 augmented the drug-induced decrease in cell viability and increased caspase-3 activity. In agreement with our findings, chemosensitization by 5005 was stronger than by 4625, a property that makes this antisense compound highly attractive for therapeutic use.
Taken together, our data confirm the favorable properties of the LNA antisense technology and demonstrate that oligonucleotide 5005 fulfils the requirement of a highly effective Bcl-2/Bcl-xL bispecific antisense compound that deserves attention for targeted intervention in apoptosis-resistant cancer. The concept of counteracting the expression of more than one cancer-relevant gene with a single functionally improved antisense sequence opens new avenues for multitarget-based cancer therapy.
